Will ORBITA change my practice? ORBITA trial: Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina

EuroIntervention 2018;14:951-954 published online ahead of print September 2018. DOI: 10.4244/EIJY18M09_2

Robert Schueler
Robert Schueler1*, MD; Rasha Al-Lamee2, MD; Felix Mahfoud3, MD; Davide Capodanno4, MD, PhD; Mirvat Al Asnag5, MD; Michael Haude6, MD
1. Department of Cardiology and Angiology, Elisabeth Hospital, Essen, Germany; 2. National Heart and Lung Institute, Imperial College London, London, and Imperial College Healthcare NHS Trust, London, United Kingdom; 3. Department of Internal Medicine III

Introduction to the session

This summary report aims to capture the content of the session at EuroPCR 2018 that reviewed the implications for clinical practice of the ORBITA trial, in order to share a critical analysis of the trial and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.

Impact of ORBITA

The impact of percutaneous coronary interventions (PCI) for stable angina on symptoms and quality of life compared to medical treatment alone is not fully understood1,2. The Objective Randomised Blinded Investigation with optimal ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Will CULPRIT-SHOCK change my practice? The CULPRIT-SHOCK trial: culprit lesion-only PCI vs. multivessel PCI in patients with acute myocardial infarction and cardiogenic shock

Latest news